Perspective Therapeutics, Inc. (“Perspective” or “the
Company”) (NYSE AMERICAN: CATX), announced today that it has
entered into a patent license agreement with Mayo Clinic for the
rights to the PSMA Alpha-PET DoubLET platform technology for the
treatment of PSMA-expressing cancers, with an initial focus on
prostate.
The PSMA Alpha-PET DoubLET platform technology represents a
potential leap forward in the field of prostate cancer diagnostics
and treatment. This leading radiopharmaceutical platform provides
detailed PET imaging-based diagnosis and dosimetry using long-lived
copper-64 (64Cu) for imaging and alpha-particle targeted RPT using
lead-212 (212Pb). It can also be used for beta-particle targeted
RPT using copper isotopes. Preclinical studies demonstrated a high
degree of radiation delivered to tumors while minimizing exposure
to critical organs and tissues.
“This innovative approach developed by Mayo Clinic allows for
more precise and personalized treatment plans,” said Thijs Spoor,
Chief Executive Officer at Perspective Therapeutics. “This new
license furthers our goal to bring new best-in-class products to
the clinic that improve efficacy and minimize side effects.”
“It is not enough to develop a more powerful therapy. We focused
on diagnostic accuracy, patient tolerance and convenience. PSMA
Alpha-PET aims to improve the overall experience of individuals
undergoing prostate cancer radiopharmaceutical therapy,” commented
co-inventor Geoff Johnson, MD, PhD, Chair of Nuclear Medicine,
Associate Director of the Mayo Clinic Comprehensive Cancer Center
and Director of the Radiopharmaceutical Trial Disease Team. “The
platform’s innovative design provides rapid and high-quality
quantitative PET imaging to guide alpha and/or beta-particle RPT,
with a reasonable workflow that patients and clinics can
follow.”
Co-inventor Mukesh Pandey, PhD, FRSC, Professor of Radiology and
Director of Mayo Clinic Molecular Imaging Research Program said,
“The team at Mayo Clinic conducted rigorous scientific experiments
to validate the specific targeting of PSMA Alpha-PET to prostate
tumors compared to other normal tissues. We are pleased to report
that this compound performed very favorably in the preclinical
setting where it had significantly less salivary gland uptake and
improved kidney clearance than comparators. PSMA Alpha-PET was also
effective in treating mice with prostate cancer tumor implants and
was well tolerated.”
Dr. Markus Puhlmann, Chief Medical Officer of Perspective
Therapeutics added, “PSMA Alpha-PET is a potentially groundbreaking
solution that addresses some of the limitations of existing
products in prostate cancer imaging and treatment. We are committed
to advancing medical technology that we believe will make a
meaningful difference in the lives of those affected by prostate
cancer.”
Mayo Clinic has a financial interest in the technology
referenced in this press release. Mayo Clinic will use any revenue
it receives to support its not-for-profit mission in patient care,
education and research.
About Prostate CancerProstate
cancer is the second-most prevalent form of cancer affecting men
worldwide, emphasizing the critical need for advanced technologies
to improve early detection and treatment outcomes. For 2023, the
Cancer Institute estimated 88,300 new cases of prostate cancer in
the US and around 34,700 deaths from the disease.
About Perspective Therapeutics, Inc.Perspective
Therapeutics, Inc., is a radiopharmaceutical company that is
pioneering advanced treatment applications for cancers throughout
the body. The Company has a proprietary technology that utilizes
the alpha emitting isotope 212Pb to deliver powerful radiation
specifically to cancer cells via specialized targeting peptides.
The Company is also developing complementary imaging diagnostics
that incorporate the same targeting peptides which provide the
opportunity to personalize treatment and optimize patient outcomes.
This “theranostic” approach enables the ability to see the specific
tumor and then treat it to potentially improve efficacy and
minimize toxicity associated with many other types of cancer
treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor
(VMT-α-NET) programs have entered Phase 1/2a imaging and therapy
trials for the treatment of metastatic melanoma and neuroendocrine
tumors at several leading academic institutions. The Company has
also developed a proprietary 212Pb generator to secure key isotopes
for clinical trial and commercial operations.
For more information, please visit the Company’s website at
www.perspectivetherapeutics.com .
Safe Harbor StatementThis press release
contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
"may," "will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "estimate," "believe," "predict,"
"potential" or "continue" or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things, the success
of Mayo Clinic’s PSMA Alpha-PET DoubLET platform as a treatment and
diagnostic option for prostate cancer; the ability for the PSMA
Alpha-Pet DoubLET platform to provide more precise and personalized
treatment plans for prostate cancer patients; the ability for the
PSMA Alpha-PET DoubLET platform to improve efficacy, minimize side
effects, and enhance the overall quality of life and experience for
patients undergoing prostate cancer therapy; the potential for the
PSMA Alpha-PET DoubLET platform to provide rapid and high quality
PET imaging that can be used to guide either alpha or beta-particle
RPT, enhancing patient workflow; the PSMA Alpha-PET DoubLET
platform’s ability to address limitations of existing products in
prostate cancer imaging and treatment; and the ability for the PSMA
Alpha-PET DoubLET platform to continue to demonstrate significantly
less salivary gland uptake and improved kidney clearance than
comparators.
The Company may not actually achieve the plans, intentions or
expectations disclosed in the forward-looking statements and you
should not place undue reliance on the forward-looking statements.
These forward-looking statements involve risks and uncertainties
that could cause the Company's actual results to differ materially
from the results described in or implied by the forward-looking
statements, including, without limitation: the Company's ability to
continue as a going concern, the potential that regulatory
authorities may not grant or may delay approval for the Company's
product candidates; uncertainties and delays relating to the
design, enrollment, completion, and results of clinical trials;
unanticipated costs and expenses; early clinical trials may not be
indicative of the results in later clinical trials; clinical trial
results may not support regulatory approval or further development
in a specified indication or at all; actions or advice of
regulatory authorities may affect the design, initiation, timing,
continuation and/or progress of clinical trials or result in the
need for additional clinical trials; the Company's ability to
obtain and maintain regulatory approval for the Company's product
candidates; delays, interruptions or failures in the manufacture
and supply of the Company's product candidates; the size and growth
potential of the markets for the Company's product candidates, and
the Company's ability to service those markets; the Company's cash
and cash equivalents may not be sufficient to support its operating
plan for as long as anticipated; the Company's expectations,
projections and estimates regarding expenses, future revenue,
capital requirements, and the availability of and the need for
additional financing; the Company's ability to obtain additional
funding to support its clinical development programs; the
availability or potential availability of alternative products or
treatments for conditions targeted by the Company that could affect
the availability or commercial potential of its product candidates;
the ability of the Company to manage growth and successfully
integrate its businesses; the Company's ability to maintain its key
employees; whether there is sufficient training and use of the
Company's products and product candidates; the market acceptance
and recognition of the Company's products and product candidates;
the Company's ability to maintain and enforce its intellectual
property rights; the Company's ability to maintain its therapeutic
isotope supply agreement with the Department of Energy; the
Company's ability to continue to comply with the procedures and
regulatory requirements mandated by the FDA for additional trials,
Phase 1 and 2 approvals, FDA Fast Track approvals, and 510(k)
approval and reimbursement codes; and any changes in applicable
laws and regulations. Other factors that may cause the Company's
actual results to differ materially from those expressed or implied
in the forward-looking statements in this press release are
described under the heading "Risk Factors" in the Company's most
recent Transition Report on Form 10-KT and the Company's most
recent Quarterly Report on Form 10-Q, each filed with the
Securities and Exchange Commission (the "SEC"), in the Company's
other filings with the SEC, and in the Company's future reports to
be filed with the SEC and available at www.sec.gov. Forward-looking
statements contained in this news release are made as of this date.
Unless required to do so by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Russo Partners, LLC
Nic Johnson or Harrison Seidner, Ph.D.
E: Nic.johnson@russopartnersllc.com
E: Harrison.seidner@russopartnersllc.com
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Apr 2023 to Apr 2024